AlzeCure Q2: Prepares for clinical studies - Redeye

Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expectations. AlzeCure recently strengthened its cash position and is moving closer to clinical trials, including a phase IIa study with NeuroRestore ACD856 in Alzheimer’s. With the successful capital raise incorporated in our model, we land in a slightly increased fair value range. This update also provides a recap of the NeuroRestore program.

Länk till analysen i sin helhet: https://www.redeye.se/research/1124999/alzecure-q2-prepares-for-clinical-studies?utm_source=finwire&utm_medium=RSS